Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17355550 | 0.93 | ALOX5AP (0.37) | ALOX5APFEN1GRM2CTSLCTSS | |
| SCHEMBL17355602 | 0.92 | CYP11B2 (0.37) | ALOX5APFEN1GRM2AKR1C3AKR1C2 | |
| SCHEMBL17355630 | 0.92 | CYP11B2 (0.37) | ALOX5APFEN1GRM2AKR1C3AKR1C2 | |
| SCHEMBL17365897 | 0.91 | CTSL (0.34) | ALOX5APFEN1CTSLCTSSCTSK | |
| SCHEMBL17355431 | 0.91 | AR (0.32) | CTSLCTSSCTSK | |
| SCHEMBL17355485 | 0.90 | GRM2 (0.35) | ALOX5APFEN1GRM2CTSLCTSS | |
| SCHEMBL17355594 | 0.89 | ALOX5AP (0.39) | ALOX5APFEN1GRM2CTSLCTSS | |
| SCHEMBL17355499 | 0.89 | CTSL (0.36) | ALOX5APFEN1GRM2CTSLCTSS | |
| SCHEMBL17355555 | 0.89 | ALOX5AP (0.34) | ALOX5APFEN1GRM2AKR1C3AKR1C2 | |
| SCHEMBL18887648 | 0.89 | ALOX5AP (0.36) | ALOX5APFEN1GRM2AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657229-B2 | Liquid crystal compound having difluoromethyleneoxy, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20150376502-A1 | LIQUID CRYSTAL COMPOUND HAVING DIFLUOROMETHYLENEOXY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2957554-A1 | LIQUID-CRYSTALLINE COMPOUND HAVING DIFLUOROMETHYLENEOXY GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2015-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376502-A1 | LIQUID CRYSTAL COMPOUND HAVING DIFLUOROMETHYLENEOXY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | C1S, CPNE4, PIEZO1 | ALOX5AP 2334/4885FEN1 1742/4885GRM2 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.